{"nctId":"NCT04688320","briefTitle":"Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE","startDateStruct":{"date":"2020-12-15","type":"ACTUAL"},"conditions":["Massive Pulmonary Embolism"],"count":310,"armGroups":[{"label":"Recombinant nonimmunogenic staphylokinase","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant nonimmunogenic staphylokinase"]},{"label":"Alteplase","type":"EXPERIMENTAL","interventionNames":["Drug: Alteplase"]}],"interventions":[{"name":"Recombinant nonimmunogenic staphylokinase","otherNames":["Fortelyzin"]},{"name":"Alteplase","otherNames":["Actillyze"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women aged 18 and over\n* Verified diagnosis of massive PE (using MSCT with PA contrast)\n* Signs of overload / dysfunction of the right ventricle (at least one) in combination with persistent arterial hypotension or shock\n* Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:\n\n  * women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);\n  * men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility)\n* Availability of signed and dated informed consent of the patient to participate in the study.\n\nExclusion Criteria:\n\n* â€¢ Increased risk of bleeding:\n\n  * Extensive bleeding at present or within the previous 6 months, hemorrhagic diathesis;\n  * Intracranial (including subarachnoid) hemorrhage at present or in history, suspected hemorrhagic stroke;\n  * A history of hemorrhagic stroke or stroke of unknown etiology;\n  * Ischemic stroke or transient ischemic attack within the last 6 months, except for the current acute ischemic stroke within 4.5 hours;\n  * A history of diseases of the central nervous system (including neoplasms, aneurysms, surgery on the brain or spinal cord);\n  * Major surgery or major trauma within the previous 3 months, recent traumatic brain injury;\n  * Long-term or traumatic cardiopulmonary resuscitation (\\> 2 min), delivery within the previous 10 days, recent puncture of an uncompressible blood vessel (eg, subclavian or jugular vein);\n  * Severe liver disease, including liver failure, cirrhosis, portal hypertension (including esophageal varices) and active hepatitis;\n  * Confirmed gastric or duodenal ulcer within the last three months;\n  * Neoplasm with an increased risk of bleeding;\n  * Concurrent administration of oral anticoagulants, for example, warfarin with an INR\\> 1.3;\n  * Arterial aneurysms, developmental defects of arteries / veins;\n  * Severe uncontrolled arterial hypertension;\n  * Acute pancreatitis;\n  * Bacterial endocarditis, pericarditis;\n  * suspicion of aortic dissecting aneurysm;\n  * any other conditions, in the opinion of the doctor, associated with a high risk of bleeding.\n* Lactation, pregnancy\n* Known hypersensitivity to Alteplase, Fortelizin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Death From All Causes","description":"The efficacy is evaluated in terms of the number of deaths from all causes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Systolic Pulmonary Artery Pressure Measures (V1, V2, V4, V5)","description":"The efficacy is evaluated in terms of systolic pulmonary artery pressure values","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemodynamic Collapse","description":"The efficacy is evaluated in terms of the number of haemodynamic collapse","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Recurrent Pulmonary Embolism (PE)","description":"The efficacy is evaluated in terms of the number of recurrent PE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Death From PE","description":"The efficacy is evaluated in terms of the number of deaths from PE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Death From All Causes","description":"The efficacy is evaluated in terms of the number of deaths from all causes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Haemodynamic Collapse Within 7 Days + Recurrent PE Within 7 Days + Death From All Causes Within 30 Days","description":"The efficacy is evaluated in terms of the number of haemodynamic collapse + recurrent PE + deaths from all causes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoint - Haemorrhagic Stroke","description":"The safety is evaluated in terms of the number of haemorrhagic stroke within 7 days of randomisation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoint - BARC Type 3+5 Bleeding","description":"The safety is evaluated in terms of the number of BARC type 3+5 bleeding. Type 3a: overt bleeding plus a hemoglobin drop of 3 to 5 g/dL; any transfusion with overt bleeding.\n\nType 3b: overt bleeding plus a hemoglobin drop of 5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring intravenous vasoactive agents.\n\nType 3c: intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal); subcategories confirmed by autopsy or imaging, or lumbar puncture; intraocular bleed compromising vision.\n\nType 5a: probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious.\n\nType 5b: definite fatal bleeding; overt bleeding or autopsy, or imaging confirmation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety Endpoint - Number and Severity of Serious Adverse Events (SAEs)","description":"The safety is evaluated in terms of the number and severity of serious adverse events (SAEs)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":145},"commonTop":["Hematuria"]}}}